스토크 테라퓨틱스(STOK)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $28.43 (-1.73%), 시가총액 $1.94B, 52주 최저~최고 $8.93 ~ $38.35.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of
스토크 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
스토크 테라퓨틱스의 현재 주가는 $28.43 (-1.73%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
스토크 테라퓨틱스의 시가총액은 약 $1.94B입니다.
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear